Impaired lipoprotein lipase activity slows TRL clearance and raises triglycerides while lowering HDL cholesterol.

An objective, evidence-based assessment of the relationship between lipoprotein lipase activity, triglyceride clearance, and HDL cholesterol.

Mechanistic explanations

Lipoprotein lipase (LPL) is the primary rate-limiting enzyme responsible for the intravascular hydrolysis of core triglycerides (TGs) carried within chylomicrons and very-low-density lipoproteins (VLDLs). Impaired LPL activity—driven by genetic variations, regulatory protein dysfunction (such as APOC2, APOA5, or GPIHBP1 deficiencies), or acquired insulin resistance—impedes this lipolytic process. The resulting delay in the clearance of these triglyceride-rich lipoproteins (TRLs) leads to their prolonged circulation and accumulation in plasma.

This clearance bottleneck directly drives two coupled metabolic abnormalities:

• Elevated Triglycerides: The accumulation of lipolysis-resistant VLDL and chylomicron remnants manifests clinically as elevated serum triglycerides (hypertriglyceridemia).
• Depressed HDL Cholesterol: Under physiological conditions, LPL-mediated lipolysis sheds redundant surface phospholipids and apolipoproteins from TRLs, transferring them to pre-beta-HDL to promote mature HDL particle formation. When TRL clearance is impaired, this transfer is halted. Furthermore, the persistent abundance of circulating TRLs drives cholesteryl ester transfer protein (CETP)-mediated lipid exchange. This process transfers triglycerides from TRLs into HDL in exchange for cholesteryl esters. The resulting triglyceride-enriched HDL particles are highly unstable and undergo rapid hydrolysis by hepatic lipase, leading to accelerated HDL catabolism and a marked reduction in plasma HDL cholesterol (HDL-C) levels.

Conversely, gain-of-function variations in the LPL pathway (such as the LPL rs328/Ser447Ter variant) enhance the fractional catabolic rate of TRLs, resulting in a cardioprotective phenotype characterized by lower triglycerides and higher HDL-C.

Clinical implications

In a 61-year-old male, impaired LPL-mediated clearance and the resulting high-triglyceride, low-HDL phenotype are major drivers of residual cardiovascular risk. This atherogenic dyslipidemia profile promotes the accumulation of highly atherogenic remnant lipoproteins, which can penetrate the arterial wall and accelerate plaque formation. Managing this pathway typically involves optimizing insulin sensitivity, implementing therapeutic lifestyle modifications, and considering pharmacotherapies (such as fibrates or emerging angiopoietin-like protein inhibitors) that modulate LPL activity and enhance TRL clearance.

Bottom line

Impaired lipoprotein lipase activity directly slows the clearance of triglyceride-rich lipoproteins. This failure in lipolysis drives a coupled metabolic cascade that elevates serum triglycerides and accelerates HDL-C catabolism, producing a highly atherogenic lipid profile.